Angion Biomedica Corp. (ANGN) 10-K Annual Report March 2023

Cover - USD ($) $ in Millions	12 Months Ended
Cover - USD ($) $ in Millions	Dec. 31, 2022	Mar. 15, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Entity Transition Report	false
Entity File Number	001-04321
Entity Registrant Name	ANGION BIOMEDICA CORP
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3430072
Entity Address, Address Line One	7-57 Wells Avenue
Entity Address, City or Town	Newton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02459
City Area Code	415
Local Phone Number	655-4899
Title of 12(b) Security	Common Stock, par value $0.01
Trading Symbol	ANGN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 34.3
Entity Common Stock, Shares Outstanding		30,114,190
Documents Incorporated by Reference	None.
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001601485
Amendment Flag	false

ChatGPT says Angion Focused on Novel Therapies, Seeks Collaborations to Expand Portfolio.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1601485/000160148523000011/angn-20221231.htm

View differences made from one year to another to evaluate Angion Biomedica Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Angion Biomedica Corp..

Continue

Assess how Angion Biomedica Corp.'s management team is paid from their Annual Proxy

Angion Biomedica Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

M & A

Mgmt Change

Other

Filter Subcategory:

All

Expense

Product

Debt

Cash Flow

Income

Other

Inside Angion Biomedica Corp.'s 10-K Annual Report:

Other - Other Highlight
In connection with these activities, we record restructuring charges at fair value for one-time employee termination benefits on the communication date from management to the employees provided that management has committed to a plan of termination, the plan identifies the employees and their expected termination dates, the details of termination benefits are complete, and it is unlikely that changes to the plan will be made or the plan will be withdrawn.

Financial - Expense Highlight
The decrease is primarily due to a decrease in personnel-related costs and expenses applied as we believe the work under U.S. Department of Defense grant had been completed in the year ended December 31, 2021.
Revenue - Product Highlight
Funds received from grants and contracts are generally deemed to be earned and recognized as revenue as allowable costs are incurred during the grant or contract period and the right to payment is realized.
Revenue - Product Highlight
Grant Revenue Our grants and contracts reimburse us for direct and indirect costs relating to the grant projects and also provide us with a pre-negotiated profit margin on total direct and indirect costs of the grant award, excluding subcontractor costs, after giving effect to directly attributable costs and allowable overhead costs.
Other - Other Highlight
At contract inception, we assess the goods or services promised within each contract, whether each promised good or service is distinct, and determine those that are performance obligations.
Financial - Expense
Research and Development Research and...Read more
Revenue - Product
This accelerated the revenue recognition,...Read more
Revenue - Product
We are also eligible to...Read more
Financial - Debt
The net non-cash charges were...Read more
Financial - Cash Flow
As a result, we recognized...Read more
Financial - Cash Flow
Liquidity and Capital Resources Sources...Read more
Financial - Expense
Since we do not intend...Read more
Financial - Shares
Pursuant to the Vifor License...Read more
Revenue - Product
To determine revenue recognition for...Read more
Financial - Expense
Research and Development Expenses Research...Read more
Financial - Income
The increase is primarily due...Read more
M & A - Other
In addition, if we resume...Read more
Other - Other
As a result, if factors...Read more
Revenue - Product
We believe this policy is...Read more
Financial - Expense
In connection with the reduction...Read more
Financial - Income
Income from upfront payments is...Read more
Other - Other
In February 2021, we generated...Read more
Financial - Expense
The Initial Public Offering and...Read more
Revenue - Product
If we raise funds through...Read more
Revenue - Product
For the year ended December...Read more
Financial - Expense
General and Administrative Expenses General...Read more
Financial - Expense
As the PSUs have a...Read more
Financial - Expense
We continued to lease office...Read more
Other - Other
Other exemptions and reduced reporting...Read more
Financial - Cash Flow
If the carrying value of...Read more
Revenue - Product
Other revenue, such as milestone...Read more
Financial - Expense
These decreases in net cash...Read more
Other - Other
For one-time employee terminations benefits,...Read more
Financial - Expense
These costs consist of termination...Read more
Financial - Expense
The discount to the settlement...Read more
Mgmt Change - Other
On March 10, 2023, Silicon...Read more
Revenue - Product
The change in net operating...Read more
Financial - Expense
We include the estimated costs...Read more
Revenue - Product
We believe the recognition of...Read more
Other - Other
We may recognize a cumulative...Read more
Other - Other
Critical Accounting Policies and Significant...Read more
Financial - Expense
This reduction was a cost-cutting...Read more
Other - Other
We recognize deferred tax assets...Read more
Other - Other
These charges are primarily one-time...Read more
Financial - Expense
We recognize research and development...Read more
Revenue - Product
Under ASC 606, we recognize...Read more
Revenue - Product
When the license is the...Read more
Financial - Expense
As such, we use significant...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Angion Biomedica Corp. provided additional information to their SEC Filing as exhibits

Exhibit 10.17: Material Contract

Exhibit 10.17(A): Material Contract

Exhibit 10.18: Material Contract

Exhibit 10.19: Material Contract

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ANGN
CIK: 1601485
Form Type: 10-K Annual Report
Accession Number: 0001601485-23-000011
Submitted to the SEC: Fri Mar 17 2023 4:24:16 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations